Miltefosine for Mucosal Leishmaniasis

Phase 2CompletedNCT00373776

AB Foundation75 enrolled

Overview

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Treat bolivian mucosal leishmaniasis with miltefosine.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Leishmaniasis

Interventions

miltefosine 2.5 mg/kg/day for 28 daysDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Mucosal leishmaniasis Exclusion Criteria: * Abnormal liver function tests (LFT) * Abnormal kidney function test * Concomitant diseases

Locations (1)

Unnamed facility

Palos Blancos, Bolivia

Outcomes

Primary Outcomes

Efficacy

Secondary Outcomes

toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.